Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia

Type 2 diabetes mellitus (T2DM) is a chronic disease with high-cost treatment. This study aimed to analyze the cost-effectiveness of T2DM treatment in hospitalized patients with complications of kidney and peripheral vascular disease (PVD) in Indonesia by focusing on patients of Health Social Securi...

Full description

Bibliographic Details
Main Authors: Akhmad Priyadi, Hikmat Permana, Ahmad Muhtadi, Sri A. Sumiwi, Rano K. Sinuraya, Auliya A. Suwantika
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Healthcare
Subjects:
Online Access:https://www.mdpi.com/2227-9032/9/2/211
_version_ 1797396361742647296
author Akhmad Priyadi
Hikmat Permana
Ahmad Muhtadi
Sri A. Sumiwi
Rano K. Sinuraya
Auliya A. Suwantika
author_facet Akhmad Priyadi
Hikmat Permana
Ahmad Muhtadi
Sri A. Sumiwi
Rano K. Sinuraya
Auliya A. Suwantika
author_sort Akhmad Priyadi
collection DOAJ
description Type 2 diabetes mellitus (T2DM) is a chronic disease with high-cost treatment. This study aimed to analyze the cost-effectiveness of T2DM treatment in hospitalized patients with complications of kidney and peripheral vascular disease (PVD) in Indonesia by focusing on patients of Health Social Security Agency (<i>BPJS Kesehatan</i>). An observational study was applied by collecting data retrospectively from patients’ medical record at the biggest public hospital in West Java Province, Indonesia. Two perspectives of payer and healthcare provider were applied to estimate the treatment cost. We considered following inclusion criteria: (i) Hospitalized T2DM patients without complication, with complications of kidney and PVD during 2014–2017; (ii) member of <i>BPJS Kesehatan</i>; (iii) >18 years old patients; and (iv) patients with complete medical record data. The results showed that the majority patients were female (56.72%), 45–64 years old (69.40%), and had a length of stay at 4–10 days (54.48%). The greatest contributions in the total treatment cost were found to be hospital room, medical services and medicines for the treatment of T2DM without complications, with complications of kidney and PVD, respectively. From the perspective of payer, the incremental cost-effectiveness ratios (ICERs) of T2DM treatment with complications of kidney and PVD would be IDR 215,723 and IDR 234,591 per 1 mg/dL blood glucose reduction, respectively. From the perspective of healthcare provider, the ICERs of T2DM treatment with complications of kidney and PVD would be IDR 166,289 and IDR 681,853 per 1 mg/dL blood glucose reduction in both perspectives (1 US$ = IDR 13,451). In a comparison with T2DM without complication, reducing 1 mg/dL blood glucose in T2DM treatment with complication of PVD would require higher cost than in T2DM treatment with complication of kidney from both perspectives.
first_indexed 2024-03-09T00:49:11Z
format Article
id doaj.art-01d94f27cb5a4ccbb0038646e26ed915
institution Directory Open Access Journal
issn 2227-9032
language English
last_indexed 2024-03-09T00:49:11Z
publishDate 2021-02-01
publisher MDPI AG
record_format Article
series Healthcare
spelling doaj.art-01d94f27cb5a4ccbb0038646e26ed9152023-12-11T17:16:53ZengMDPI AGHealthcare2227-90322021-02-019221110.3390/healthcare9020211Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in IndonesiaAkhmad Priyadi0Hikmat Permana1Ahmad Muhtadi2Sri A. Sumiwi3Rano K. Sinuraya4Auliya A. Suwantika5Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung 40132, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Bandung 40132, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung 40132, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung 40132, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung 40132, IndonesiaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung 40132, IndonesiaType 2 diabetes mellitus (T2DM) is a chronic disease with high-cost treatment. This study aimed to analyze the cost-effectiveness of T2DM treatment in hospitalized patients with complications of kidney and peripheral vascular disease (PVD) in Indonesia by focusing on patients of Health Social Security Agency (<i>BPJS Kesehatan</i>). An observational study was applied by collecting data retrospectively from patients’ medical record at the biggest public hospital in West Java Province, Indonesia. Two perspectives of payer and healthcare provider were applied to estimate the treatment cost. We considered following inclusion criteria: (i) Hospitalized T2DM patients without complication, with complications of kidney and PVD during 2014–2017; (ii) member of <i>BPJS Kesehatan</i>; (iii) >18 years old patients; and (iv) patients with complete medical record data. The results showed that the majority patients were female (56.72%), 45–64 years old (69.40%), and had a length of stay at 4–10 days (54.48%). The greatest contributions in the total treatment cost were found to be hospital room, medical services and medicines for the treatment of T2DM without complications, with complications of kidney and PVD, respectively. From the perspective of payer, the incremental cost-effectiveness ratios (ICERs) of T2DM treatment with complications of kidney and PVD would be IDR 215,723 and IDR 234,591 per 1 mg/dL blood glucose reduction, respectively. From the perspective of healthcare provider, the ICERs of T2DM treatment with complications of kidney and PVD would be IDR 166,289 and IDR 681,853 per 1 mg/dL blood glucose reduction in both perspectives (1 US$ = IDR 13,451). In a comparison with T2DM without complication, reducing 1 mg/dL blood glucose in T2DM treatment with complication of PVD would require higher cost than in T2DM treatment with complication of kidney from both perspectives.https://www.mdpi.com/2227-9032/9/2/211blood glucose reduction<i>BPJS Kesehatan</i>ICERperspectivehealthcare providerpayer
spellingShingle Akhmad Priyadi
Hikmat Permana
Ahmad Muhtadi
Sri A. Sumiwi
Rano K. Sinuraya
Auliya A. Suwantika
Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
Healthcare
blood glucose reduction
<i>BPJS Kesehatan</i>
ICER
perspective
healthcare provider
payer
title Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_full Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_fullStr Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_full_unstemmed Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_short Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
title_sort cost effectiveness analysis of type 2 diabetes mellitus t2dm treatment in patients with complications of kidney and peripheral vascular diseases in indonesia
topic blood glucose reduction
<i>BPJS Kesehatan</i>
ICER
perspective
healthcare provider
payer
url https://www.mdpi.com/2227-9032/9/2/211
work_keys_str_mv AT akhmadpriyadi costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT hikmatpermana costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT ahmadmuhtadi costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT sriasumiwi costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT ranoksinuraya costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia
AT auliyaasuwantika costeffectivenessanalysisoftype2diabetesmellitust2dmtreatmentinpatientswithcomplicationsofkidneyandperipheralvasculardiseasesinindonesia